Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


No effects of type II diabetes on aggressiveness of prostate cancer; long-term survival worse


Researchers at Fox Chase Cancer Center found no effects of type II diabetes on aggressiveness of prostate cancer but found that long-term survival is worse. The findings were presented today at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Denver, Colo.

Previous research suggests that insulin may spur the growth of prostate cancer cells. In type II diabetes, the body fails to properly use insulin, which can lead to an excessive amount of insulin in the blood.

"We looked at several key pretreatment factors used to stage the prostate cancer," explained Khanh H. Nguyen, M.D., lead author of the Fox Chase study and a resident in the radiation oncology department at Fox Chase. "These factors include the initial PSA, Gleason score and T-stage. The men with type II diabetes didn’t have a significantly different initial profile for their prostate cancer than the men without diabetes. Additionally, type II diabetes did not appear to influence the rates of PSA failures or distant metastases. However, men with type II diabetes had significantly worse long-term overall survival."

The patient cohort for this study included 1,512 men with localized prostate cancer treated with radiation therapy between April 1989 and October 2001. Of these, 1,306 men had no history of type II diabetes (NDM) while 206 men had diabetes (DM-II), which was managed with diet, exercise or medications other than insulin.

The study did not detect significant differences in the initial PSA, Gleason score, or T-stage between the men with and without diabetes. The median initial PSA for men with NDM was 8.2 compared to 8.7 for men with DM-II. Twenty-eight percent of NDM cases versus 26 percent of those with DM-II had a Gleason score of 7-10. By T-stage, 94 percent of NDM patients and 93 percent of DM-II patients had stage T1a-2c disease.

The researchers also looked at the effect of DM-II on long-term radiation treatment outcomes. At 5 years, 27.2 percent (355) of men with NDM had PSA failures versus 23.8 percent (49) of men with DM-II. Seven percent (92) of NDM patients had distant metastases compared to 4.9 percent (10) with DM-II

. Of the patients with NDM, 3.1 percent (41) died of prostate cancer versus 2.4 percent (5) of patient with DM-II. "Although men with type II diabetes did not have significantly different treatment outcomes, having the disease had a detrimental effect on overall survival," said Nguyen.

Of the men without diabetes, 19.1 percent (250) died from all causes, compared to 22.8 percent (47) deaths overall for those with DM-II. This result was statistically significant even after adjusting for the key pretreatment factors.

Nguyen, now a radiation oncologist at the University of Tennessee Medical Center in Knoxville, Tenn., concluded, "The degree of hyperinsulinemia in type II diabetes can vary considerably and may obscure the true impact of insulin on the natural history of prostate cancer. Despite laboratory and epidemiological data suggesting an effect of insulin on prostate cancer growth, in our patient cohort, diabetes did not appear to influence the aggressiveness of prostate cancer at presentation.

"However, type II diabetes conferred a significantly higher overall mortality. Aggressive management of diabetes with diet, exercise, and medications may improve the survival of cancer patients."

Karen C. Mallet | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung

nachricht High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Oasis of life in the ice-covered central Arctic

24.10.2016 | Earth Sciences

‘Farming’ bacteria to boost growth in the oceans

24.10.2016 | Life Sciences

Light-driven atomic rotations excite magnetic waves

24.10.2016 | Physics and Astronomy

More VideoLinks >>>